| Species |
Human |
| Protein Construction |
HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer [Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and YTDNWLAVY peptide]
Accession # Q5SUL5(HLA-A*01:01)&P61769(B2M)&YTDNWLAVY |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.50 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC. |
| Synonyms |
DSG3; DSG-3; Desmoglein-3; PVA; CDHF6; DG3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
